Can a common arthritis drug stop Parkinson's before it starts?

NCT ID NCT06996652

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times

Summary

This study tests whether adalimumab, an anti-inflammatory drug, can prevent brain changes linked to Parkinson's disease in 108 people with REM sleep behavior disorder (RBD). RBD often precedes Parkinson's. Participants will receive adalimumab or a placebo every two weeks for two years, and researchers will monitor brain activity using PET scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REM SLEEP BEHAVIOR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas

    Las Vegas, Nevada, 89106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

  • Emory University School of Medicine

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Medical University of South Carolina

    Charleston, South Carolina, 29403, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montreal Neurological Institute-Hospital at McGill University

    Montreal, Quebec, H3A 2B4, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Parkinson's Disease & Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Colorado Anschutz

    Aurora, Colorado, 80045, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • University of Minnesota

    Minneapolis, Minnesota, 55414, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Health Science Center- San Antonio

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas Houston Medical Center

    Houston, Texas, 77030, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Weill Medical College of Cornell University

    New York, New York, 10021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Yale Medicine

    North Haven, Connecticut, 06473, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Adalimumab (a drug that reduces inflammation, given as a shot every 2 weeks)

What this could lead to

If it works, this could point toward a way to delay or prevent Parkinson's disease in people with REM sleep behavior disorder.

What could go wrong

This is an early phase 2 study with only 108 people. It tests a brain scan change, not whether symptoms actually improve. Adalimumab can increase infection risk.

Conditions

The condition(s) this trial relates to.

REM sleep behavior disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.